Top Page
Actinogen Medical
(Sydney:ACW)
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Actinogen Medical Business Overview & Revenue Model
Actinogen Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.29M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -15.01M | -15.01M | -12.84M | -15.22M | -12.72M | -5.35M |
| Net Income | -14.73M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 24.48M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 16.50M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 3.26M | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 6.15M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 18.34M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -7.59M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -7.56M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.02K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 14.65M | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Actinogen Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$105.20M | 15.29 | 27.24% | 2.63% | 0.65% | -9.90% | |
56 Neutral | $181.39M | ― | -75.99% | ― | ― | 10.91% | |
56 Neutral | AU$90.43M | -9.45 | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | AU$87.00M | ― | -42.68% | ― | ― | 63.46% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% | |
34 Underperform | AU$66.74M | -1.35 | -100.67% | ― | 1114.27% | 85.66% |
Actinogen Medical Corporate Events
Actinogen Medical Limited has announced the quotation of 251,050 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 5, 2025. This move marks a significant step for the company, potentially enhancing its market presence and providing additional capital for its operations, which could positively impact its stakeholders.
Actinogen Medical Limited has announced the quotation of 1,078,721 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of December 1, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and support ongoing research and development activities, potentially strengthening its position in the biotechnology sector.
Actinogen Medical Limited has announced the issuance of 2,769,826 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code ACW. This move is part of the company’s strategic efforts to enhance its capital structure and support its ongoing research and development activities, potentially strengthening its position in the biotechnology sector and providing new opportunities for stakeholders.
Actinogen Medical announced the results of its Annual General Meeting, where all resolutions, including the approval of increased placement capacity, were carried. The company is advancing its clinical trials for Xanamem, a promising treatment for Alzheimer’s and depression, with significant progress in ongoing trials. The XanaMIA Phase 2b/3 trial for Alzheimer’s is set to be fully enrolled by the end of 2025, with initial results expected in early 2026. Actinogen’s efforts in controlling brain cortisol levels through Xanamem have shown promising safety and efficacy in clinical trials, reinforcing its potential impact on the treatment of neurological diseases.
Actinogen Medical announced that its CEO and CFO will present at the Bell Potter Healthcare Conference 2025, highlighting their lead compound, Xanamem, which targets brain cortisol to slow Alzheimer’s progression and treat depression. The company is conducting multiple clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, with promising results showing significant benefits on depressive symptoms and cognitive function. These developments could strengthen Actinogen’s position in the biotechnology industry and offer new hope for patients with debilitating neurological conditions.
Actinogen Medical held its 2025 Annual General Meeting in Sydney, where the Chair and CEO presented updates on their clinical trials and strategic direction. The company is advancing its XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with full enrollment expected by the end of 2025 and initial results in early 2026. The XanaCIDD trial for depression showed significant benefits, reinforcing the potential of Xanamem in treating cognitive and depressive symptoms. These developments position Actinogen as a promising player in the biotechnology industry, with potential implications for stakeholders in terms of future treatment options and market growth.
Actinogen Medical announced that the independent Data Monitoring Committee has recommended the continuation of the XanaMIA phase 2b/3 trial for Alzheimer’s without any amendments after reviewing safety data from 153 participants. This decision marks a positive step for the company’s development of Xanamem, a promising therapy targeting elevated cortisol levels in the brain, which is linked to Alzheimer’s progression and depressive symptoms. The trial is expected to be fully enrolled by the end of 2025, with interim results anticipated in early 2026, potentially impacting the company’s position in the neurological treatment market.
Actinogen Medical announced its participation at the BIO-Europe 2025 conference in Vienna, where its executives will engage with international investors and potential biopharma partners to discuss their late-stage clinical trial program for Alzheimer’s disease. The company is conducting a pivotal phase 2b/3 trial for Alzheimer’s, with interim results expected early next year and final results in late 2026. This conference provides an opportunity to explore regional collaborations to accelerate the development of Xanamem, which has shown promising results in controlling elevated cortisol levels in the brain, a factor linked to Alzheimer’s progression and depressive symptoms.
Actinogen Medical announced a live webinar to discuss recent progress and upcoming milestones, highlighting the development of their lead compound, Xanamem, for Alzheimer’s Disease and Depression. The company is conducting clinical trials in Australia and the US, with promising results from previous studies showing significant benefits in depression symptoms and cognitive function. The ongoing trials aim to further validate Xanamem’s efficacy and safety, potentially impacting the treatment landscape for these debilitating conditions.
Actinogen Medical announced a live webinar scheduled for October 28, 2025, where CEO Dr. Steven Gourlay and other leaders will discuss the company’s recent progress and upcoming milestones. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant developments expected in 2026. This announcement highlights Actinogen’s commitment to addressing unmet medical needs in neurological and neuropsychiatric diseases, potentially impacting its market position and offering hope for stakeholders seeking new treatments.
Actinogen Medical has announced accelerated enrolment in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim analysis scheduled for January 2026 and final results expected in mid-Q4 2026. The company also reported a successful meeting with the FDA, paving the way for a streamlined path to marketing approval and enhancing its potential for partnerships. Additionally, Actinogen has launched an Investor Hub to engage shareholders and successfully completed a pharmacokinetic trial confirming the efficacy of Xanamem’s commercial formulation. These developments signify significant progress in Actinogen’s clinical and commercial strategies, potentially strengthening its position in the Alzheimer’s treatment market.
Actinogen Medical announced that its CEO, Dr. Steven Gourlay, presented at the Canaccord Drug & Device Conference, highlighting the company’s progress with Xanamem, an oral therapy targeting brain cortisol to treat Alzheimer’s and depression. The presentation emphasized the drug’s promising clinical development, upcoming milestones, and its potential to meet the high demand for effective Alzheimer’s treatments. Actinogen’s ongoing clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, demonstrate significant benefits in managing symptoms, reinforcing Xanamem’s potential impact on the market.
Actinogen Medical has received approval for an Advance Overseas Finding, allowing them to claim an additional $1.9 million in research and development tax incentives for the 2025 financial year. This approval increases their total RDTI rebate to over $7.3 million, which will support their ongoing Alzheimer’s phase 2b/3 clinical trial. The trial is a significant step in their efforts to develop Xanamem as a treatment for Alzheimer’s, with interim results expected in January 2026 and final results in late 2026. This financial boost is crucial as the company approaches key milestones in its clinical trials, potentially strengthening its position in the biotechnology industry and offering hope for stakeholders looking for advancements in Alzheimer’s treatment.
Actinogen Medical has announced the early completion of pTau screening in its XanaMIA Alzheimer’s trial due to strong recruitment, with final results expected by mid-Q4 2026. The increased participant enrollment is set to enhance the trial’s statistical power, potentially strengthening Xanamem’s positioning as a viable oral therapy for Alzheimer’s, offering safety and efficacy advantages over existing treatments.
Actinogen Medical is advancing its revolutionary oral therapeutic, Xanamem, through pivotal trials aimed at transforming the treatment landscape for Alzheimer’s disease and major depressive disorder. This advancement reflects the company’s commitment to improving lives through precision and innovation, potentially impacting its operations and industry positioning significantly.
Actinogen Medical Limited has announced its 2025 Annual General Meeting (AGM) of Shareholders, scheduled to take place in person on November 19, 2025, at K&L Gates in Sydney. Shareholders are encouraged to lodge their proxy forms online, as hard copies of the meeting notice will not be sent unless specifically requested. This move aligns with recent legislative changes and reflects the company’s commitment to digital communication, potentially enhancing shareholder engagement and operational efficiency.
Actinogen Medical has received a $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending approval. This funding is crucial as the company progresses towards key milestones in its Alzheimer’s phase 2b/3 clinical trial, with interim results expected in January 2026 and final results in Q4 2026. The rebate supports Actinogen’s financial strategy and underscores its commitment to advancing its clinical trials, potentially strengthening its position in the biotechnology industry.
Actinogen Medical announced the date for its Annual General Meeting, set for November 19, 2025, where the re-election and appointment of directors will be discussed. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant progress in its XanaMIA and XanaCIDD trials, which could impact the treatment landscape for these conditions.
Actinogen Medical Limited announced the cessation of 1,600,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future prospects.
Actinogen Medical has reached a significant milestone by securing agreement with the FDA on the necessary steps for US marketing approval of Xanamem for Alzheimer’s disease. This includes the design of a pivotal Phase 3 trial and other clinical and nonclinical activities. The FDA’s guidance enables Actinogen to move forward confidently with its development plans and enhances its positioning for discussions with potential partners. This development aligns with global regulatory efforts to find more effective therapies for Alzheimer’s, potentially impacting stakeholders positively by advancing treatment options.
Actinogen Medical has launched a new Investor Hub to enhance engagement with shareholders, offering a centralized platform for accessing company updates and interacting with the leadership team. This initiative comes as the company approaches key milestones in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim results expected in early 2026, potentially impacting its market position and stakeholder interests.